Market research
GLAXO.NSE GlaxoSmithKline Pharmaceuticals Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 497B
- P/E ratio
- 46.08
- Analyst target
- 3081
- Dividend yield
- 0.0%
- Beta
- 0.06
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- INE159A01016
- Market cap
- 497B
- P/E ratio
- 46.08
- Analyst target
- 3081
- Dividend yield
- 0.0%
- Beta
- 0.06
About
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GLAXO.NSE discussion.
5 years, 5 months ago
GlaxoSmithKline Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 1.2% above its 200 day moving average.
From a valuation standpoint, the stock is 56.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 7.5.
GlaxoSmithKline Pharmaceuticals Limited's total revenue rose by 10.1% to $9B since the same quarter in the previous year.
Its net income has increased by 123.7% to $2B since the same quarter in the previous year.
Based on the above factors, GlaxoSmithKline Pharmaceuticals Limited gets an overall score of 3/5.